Exhibit 99.2
                                                                    ------------

VASO ACTIVE PHARMACEUTICALS, INC.                   99 Rosewood Drive. Suite 260
                                                    Danvers, Massachusetts 01923


                                  NEWS RELEASE


FOR IMMEDIATE RELEASE                           CONTACT:             Matt Carter
                                                            978-750-1991 Ext. 28
                                                           mcarter@vasoactive.us
                                                           ---------------------


               VASO ACTIVE STOCK NOW QUOTED ON OTC BULLETIN BOARD
               --------------------------------------------------

     DANVERS, Mass. - (Business Wire) - February 24, 2006 - Vaso Active
Pharmaceuticals, Inc. announced that its Class A Common Stock, par value $0.0001
per share, has been approved for quotation on the OTC Bulletin Board, commencing
Friday, February 17, 2006. The Class A Common Stock is quoted on the OTC
Bulletin Board under the symbol "VAPH.ob."

     "Having our stock quoted on the OTC Bulletin Board is a significant
development for Vaso Active and advances our efforts to improve our visibility
and enhances our position in the financial markets," stated Joseph Frattaroli,
President and CFO of Vaso Active.

     Vaso Active Pharmaceuticals, Inc, is an early stage company that focuses on
commercializing, marketing and selling over-the-counter pharmaceutical products
that incorporate either a patented transdermal technology ("VALE") or a
proprietary topical technology ("PENtoCORE").



     The unique VALE technology is a patchless, lipid-based delivery system that
uses an active process, incorporating chemical vasodilators, to deliver drugs
through the skin and into the bloodstream. Products utilizing this technology
are currently in development through BioChemics, Inc.

     The PENtoCORE technology is a topical formulation and the Company is
currently marketing three products that incorporate this technology: OSTEON (for
temporary relief from minor arthritis pain), A-R EXTREME (for temporary relief
from minor muscle and joint pain associated with athletic activity) and TERMIN8
(for athlete's foot fungal infections).


FORWARD-LOOKING STATEMENTS
Certain statements contained herein constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on current expectations, estimates
and projections about the Company's industry, management's beliefs and certain
assumptions made by management. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are difficult to
predict. Because such statements involve risks and uncertainties, the actual
results and performance of the Company may differ materially from the results
expressed or implied by such forward-looking statements. Given these
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Unless otherwise required by law, the Company also
disclaims any obligation to update its view of any such risks or uncertainties
or to announce publicly the result of any revisions to the forward-looking
statements made here; however, readers should review carefully reports of
documents the Company files periodically with the SEC.

          Contact:
Matt Carter
Vaso Active Pharmaceuticals, Inc.
978-750-1991 Ext. 28
       mcarter@vasoactive.us
       ---------------------


                                      # # #